First MCT8 deficiency therapy approved
Clinical studies showed reductions in circulating thyroid hormone levels and changes in heart rate and systolic blood pressure.
-
By
-
Kathryn Wighton
-
September 29, 2026
-
-
1
The FDA approved tiratricol (Emcitate) for treating peripheral thyrotoxicosis in patients with MCT8 deficiency.
-
2
MCT8 deficiency, also known as Allan-Herndon-Dudley syndrome, primarily affects males and is caused by a faulty gene.
-
3
Tiratricol can enter cells independently of the MCT8 transporter, reducing elevated thyroid hormone levels in the blood.
-
4
Two clinical studies demonstrated tiratricol's efficacy in lowering thyroid hormone levels and improving cardiovascular symptoms.
-
5
Common adverse effects of tiratricol include diarrhea, vomiting, rash, and excessive sweating, with specific medication interactions noted.